Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 2
2014 2
2015 2
2016 3
2017 4
2018 6
2019 5
2020 5
2021 7
2022 3
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Pathology of Lung Cancer.
J Saller J, Boyle TA. J Saller J, et al. Among authors: boyle ta. Cold Spring Harb Perspect Med. 2022 Mar 1;12(3):a037812. doi: 10.1101/cshperspect.a037812. Cold Spring Harb Perspect Med. 2022. PMID: 34751163 Free PMC article. Review.
PD-L1 Expression in Lung Cancer.
Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. Yu H, et al. Among authors: boyle ta. J Thorac Oncol. 2016 Jul;11(7):964-75. doi: 10.1016/j.jtho.2016.04.014. Epub 2016 Apr 23. J Thorac Oncol. 2016. PMID: 27117833 Free PMC article. Review.
RNA sequencing steps toward the first line.
Boyle TA, Bossler AD. Boyle TA, et al. Cancer. 2023 Aug 1;129(15):2294-2296. doi: 10.1002/cncr.34801. Epub 2023 Apr 25. Cancer. 2023. PMID: 37096746
Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
Shields MD, Hicks JK, Boyle TA, Haura EB, Creelan BC. Shields MD, et al. Among authors: boyle ta. J Thorac Oncol. 2021 Mar;16(3):e15-e17. doi: 10.1016/j.jtho.2020.09.020. J Thorac Oncol. 2021. PMID: 33641722 Free article. No abstract available.
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. Saltos AN, et al. Among authors: boyle ta. Lung Cancer. 2023 Sep;183:107313. doi: 10.1016/j.lungcan.2023.107313. Epub 2023 Jul 22. Lung Cancer. 2023. PMID: 37499521 Clinical Trial.
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.
Zheng H, Yu X, Ibrahim ML, Foresman D, Xie M, Johnson JO, Boyle TA, Ruffell B, Perez BA, Antonia SJ, Ready N, Saltos AN, Cantwell MJ, Beg AA. Zheng H, et al. Among authors: boyle ta. Cancer Immunol Res. 2023 Apr 3;11(4):466-485. doi: 10.1158/2326-6066.CIR-22-0927. Cancer Immunol Res. 2023. PMID: 36757308 Free PMC article.
45 results